M

Merck

Makes medicines, vaccines and animal treatments

Regulatory Affairs Intern

InternshipDeadline 12/31/26
No salary listed
Bachelor's
Dubai - United Arab Emirates
HybridHybrid work in Dubai; applicants must be UAE Nationals.
Biology & BiotechRegulatory & Quality (Life Sciences)
Canada Citizenship Required

About the job

Requirements
  • Applicants must be UAE Nationals (Emirati) with a valid Family Book.
  • Applicants must be currently pursuing or have recently completed a degree in Pharmacy, Life Sciences, Medicine, or a related field.
  • Applicants must be graduating in Q2 of 2027 or later.
  • Applicants must be fluent in English and Arabic.
  • Applicants must be available for a full- or part-time internship lasting 4–8 weeks.
  • Applicants should demonstrate attention to detail and willingness to learn.
Responsibilities
  • Support the preparation and organization of regulatory documentation.
  • Assist with regulatory database and system updates.
  • Contribute to lifecycle management activities for registered products.
  • Support administrative and operational tasks within the Regulatory Affairs team.

About the company

Merck develops prescription medicines, vaccines and veterinary treatments for patients, health systems and animal owners worldwide. Its vaccine portfolio includes Gardasil 9, which helps prevent cancers and other diseases caused by several types of human papillomavirus. The company takes potential treatments through laboratory research and clinical trials, then manufactures and sells approved products to drug distributors, hospitals, physicians and governments. Its animal health division sells medicines and vaccines to veterinarians, farmers and pet owners, while selected drug partnerships also earn shared profits or royalties. Founded in 1891, Merck is headquartered in Rahway, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Rahway, New Jersey

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. employees build retirement benefits: Merck pairs a defined benefit pension with a matching 401(k).
  • Scientists work within a large research network: Merck reports approximately 24,700 employees in R&D.
  • Animal health adds growth: August 2026 results report Q2 sales of $1.8 billion, up 8% year over year.

What critics are saying

  • Job security faces cuts: Merck's active restructuring program eliminates roles and shrinks its global real estate footprint.
  • Keytruda protection narrows: its main U.S. patent expires in 2028, with additional patents expiring in 2029.
  • Revenue is concentrated: August 2026 results show Keytruda products generated $8.4 billion of Merck's $16.6 billion Q2 sales.

What makes Merck unique

  • Merck extends into farm technology: SenseHub continuously monitors livestock for behavioral and physiological changes.
  • Merck publishes open medical knowledge: its Manuals give clinicians and patients free online references.
  • Merck's donation commitment is open-ended: Mectizan supplies for river blindness continue for as long as needed.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

-19%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Oct 29th, 2026
Merck raises outlook on lower tax rate as Q3 sales rise 5% to $18.1B

Merck raised its full-year earnings outlook, helped by a lower tax rate, and its shares rose about 5% in Thursday morning trading. Third-quarter sales rose 5% to about $18.1 billion, though about $550 million of that came from the timing of customer purchases. Adjusted earnings per share fell 3% to $2.49. Spending on launches and research outpaced sales, and interest expense climbed. Merck now expects a non-GAAP tax rate of 32% to 33%, down from 35% to 36%. Keytruda Qlex, a shot injected under the skin, brought in $830 million, up from $463 million last quarter. Winrevair sales rose 93% to $694 million. Generic competition hit older drugs; Bridion sales fell 67%. Keytruda's main US patent expires in 2028.

Yahoo Finance
Oct 29th, 2026
Merck beats Q3 estimates with $18.1B revenue and raises 2026 profit outlook

Merck beat third-quarter 2026 expectations and raised its full-year profit outlook. Shares rose more than 2% in premarket trading on Thursday. Earnings per share were $2.49, against a consensus estimate of $2.09. Revenue reached $18.1 billion, up 4% excluding foreign exchange effects, ahead of the $17.28 billion analysts expected. Cancer drug Keytruda sold $8.6 billion, up 6%, including $830 million from its subcutaneous version, Keytruda Qlex. Winrevair, a treatment for pulmonary arterial hypertension, brought in $694 million, up 93%. Gardasil vaccine sales rose 14% to about $2 billion, and Animal Health revenue grew 4% to $1.7 billion. Merck now expects 2026 earnings per share of $2.77 to $2.82, up from $2.66 to $2.76. It narrowed its revenue guidance to between $66.8 billion and $67.3 billion.

Yahoo Finance
Oct 28th, 2026
Merck earnings preview: flat Q3 revenue expected after $16.61B last quarter

Merck (NYSE:MRK) reports third-quarter earnings on Thursday before market open. It is the first of its peers to report this season. Analysts expect revenue to be flat year on year, slowing from a 3.7% rise in the same quarter last year. Estimates have largely held steady over the past 30 days. Last quarter, Merck beat revenue expectations with $16.61 billion, up 5.1% year on year. It also beat analysts' earnings per share estimates but missed full-year EPS guidance estimates. Pharmaceutical shares have risen 3.6% on average over the last month. Merck is down 4.5% over the same period.

Yahoo Finance
Oct 28th, 2026
Merck's oncology wins lift outlook, but 110x P/E clouds its $141.82 share price

Merck (MRK) is drawing investor attention after oncology trials showed meaningful survival benefits for KEYTRUDA, sacituzumab tirumotecan, and a melanoma vaccine developed with Moderna. The shares closed at $141.82, down 4.37% over seven days and 4.68% over 30 days. They are still up 33.23% this year and 67.74% over one year in total shareholder return. A popular narrative puts fair value at $159.76, making the stock 11% undervalued. Merck plans more than 20 new growth drivers, with management pointing to over $70 billion in mid-2030s revenue potential to offset the KEYTRUDA loss of exclusivity. Valuation remains contested. Merck trades at 110.3 times earnings, against a fair ratio of 50.2, a US pharmaceuticals average of 15.7, and peers at 33.9. Its profit margin is 4.8%.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.